How is viral safety ensured in biopharmaceutical manufacturing?

Viral safety relies on a three-pronged approach. Prevention: using well-characterized cell lines, testing raw materials (bovine-derived components), and in-process testing of cell banks and harvest. Inactivation: low pH hold (3.5-3.7 for 30-60 min, effective for enveloped viruses), solvent/detergent treatment, and pasteurization for specific products. Removal: virus filtration (20-50 nm nanofiltration removes even small non-enveloped viruses), and chromatography provides additional clearance. Validation uses model viruses representing various classes and sizes (MuLV, MVM, PRV, Reo3). Total clearance demonstrated must exceed estimated viral load. Regulatory agencies require defined log reduction values across orthogonal steps.